1.
CAMMS323: Comparison of Alemtuzumab and Rebif Efficacy in Multiple ...
Alemtuzumab will be administered in two annual cycles, once at the beginning of the study and again 1 year later. Rebif® will be self-injected 3 times per ...
2.
Contact Genzyme with Questions About Campath
If you would like to contact Genzyme Medical Information with questions about Genzyme Oncology or our products, please fill in the fields below (required ...
3.
Genzyme Oncology
Genzyme Oncology has a full pipeline of innovative drug candidates derived from diverse technologies. The combination of new, sophisticated molecular ...
4.
Genzyme Oncology
Genzyme Corp. (Nasdaq: GENZ) announced on Dec 5, 2007 that the company has completed enrollment of a phase 2 clinical trial examining the safety and ...
5.
Genzyme Oncology
Genzyme Oncology is building a foundation in cancer treatment with a strong focus on discovery in both antibody and small molecule based therapies. ...
6.
Genzyme Oncology
Our lead products are Campath® (alemtuzumab), a humanized monoclonal antibody and ... Genzyme Oncology's product development expertise and strong research ...
7.
Genzyme Oncology Clinical Trials
For more information about these trials, please contact MedInfo@genzyme.com or 617-252-7832.
8.
Genzyme Oncology
Genzyme Oncology has a full pipeline of innovative drug candidates derived from diverse technologies. The combination of new, sophisticated molecular ...
9.
Genzyme Oncology
Genzyme Oncology is building a foundation in cancer treatment with a strong focus on discovery in both antibody and small molecule based therapies. ...
10.
Genzyme Oncology Antibody Therapeutics Program
WARNING: CYTOPENIAS, INFUSION REACTIONS, AND INFECTIONS.